Professor Sir Mark Caulfield MD FRCP FAHA FESC FBHS HonFPharmacol FMedSci
Professor Sir Mark Caulfield is Professor of Clinical Pharmacology at Queen Mary University of
London and the Vice Principal for Health for Queen Mary’s Faculty of Medicine and Dentistry.
Professor Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and
trained in Clinical Pharmacology at St Bartholomew’s Hospital, he developed a research programme
in molecular genetics of hypertension and translational clinical research.
At Queen Mary University of London Professor Caulfield has made contributions to the discovery of
genes related to blood pressure, cardiovascular health, cancer and rare diseases. His research has
changed national and international guidance for high blood pressure.
He has won the Lily Prize of the British Pharmacology Society, the Bjorn Folkow Award of the
European Society of Hypertension 2016 and the Franz Volhard Award of the International Society of
Hypertension in 2018.
Professor Caulfield was appointed Chief Scientist for Genomics England in 2013, charged with
delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and
infection. He was instrumental in delivering the 100,000 Genomes Project which has delivered lifechanging results for many patients. He worked with NHS England to co-create the National Genomic
Test Directory, which offers equitable access for 56 million people to appropriate genomic tests.
Professor Caulfield was awarded a knighthood in 2019 for his leadership of the 100,000 Genomes
Project.
He is a member of the Barts Health NHS Trust Board, the Barking, Havering and Redbridge University
Hospitals NHS Trust, the MedCity Board and is President of the British Pharmacological Society.
Sir Mark Caulfield
Professor of Clinical Pharmacology
Queen Mary University of London